Bei Akademie registrieren
Sartorius Stedim, FR0013154002

October 22 results call sets focus for Sartorius Stedim stock

Published on 10/17/2026 at 10:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sartorius Stedim stock has an October 22 results call. Fiscal 2026 guidance targets 6 to 10 percent sales growth in constant currencies.

Business outlook and dates

  • Management has scheduled the nine-month 2026 results conference call for October 22, 2026.
  • Fiscal 2026 guidance calls for sales growth of 6 to 10 percent in constant currencies.
  • The company reported an underlying EBITDA margin of 30.8 percent for 2025.
Pop-Art-Comicbild mit stilisierten Bioreaktoren und Zellkulturen im Lichtenstein-Stil
Sartorius Stedim Biotech Pop-Art-Comic mit stilisierten Bioreaktoren und bunten Zellkulturen im Retro-Stil, ISIN FR0013154002, Illustration mit AI erstellt.

Market context: Market report CAC 40.

Sartorius Stedim Biotech has scheduled its conference call on nine-month 2026 results for October 22, 2026, at 1 p.m. CEST, according to the company's investor-relations page.

Weekend trading

The Lang & Schwarz page for Sartorius Stedim showed no live weekend quote on October 16, 2026. The next price is shown from the start of trading by the continuously updated real-time quote of Sartorius Stedim stock.

Business outlook

For fiscal year 2026, Sartorius Stedim Biotech expects sales revenue to increase by between 6 and 10 percent in constant currencies. The company also expects its underlying EBITDA margin to rise to slightly above 31 percent. These figures and the outlook are presented on the company's investor-relations page.

Next Xetra session

The next Xetra session follows the weekend. Sartorius Stedim's scheduled results conference call is dated October 22, 2026, according to the company's investor-relations page.

Disclaimer...
en | FR0013154002 | SARTORIUS STEDIM | boerse | 70346801 | bgmi